Gyre Therapeutics, Inc. (GYRE) Operating income 2016–2025
Gyre Therapeutics, Inc. (GYRE) annual operating income history from SEC filings — each fiscal year as reported.
$11.5MFY2025 · since FY2016: -$20.4M → $11.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $11.5M | -28.9% |
| FY2024 | $16.2M | +124.0% |
| FY2023 | -$67.2M | -830.5% |
| FY2022 | $9.2M | +110.5% |
| FY2021 | -$87.9M | -53.2% |
| FY2020 | -$57.4M | -0.2% |
| FY2019 | -$57.3M | -69.3% |
| FY2018 | -$33.8M | -55.0% |
| FY2017 | -$21.8M | -6.9% |
| FY2016 | -$20.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GYRE financial trends
GYRE RevenueGYRE Net incomeGYRE Net marginGYRE Gross profitGYRE Gross marginGYRE Operating marginGYRE Operating cash flowGYRE Free cash flowGYRE Capital expendituresGYRE Return on equityGYRE Stock buybacksGYRE Dividends paidGYRE Total assetsGYRE Total liabilitiesGYRE Shareholders’ equityGYRE overview →